Genentech attempts to keep Avastin's breast cancer indication

08/7/2011 | Genetic Engineering & Biotechnology News

In a post-hearing document, Genentech asked the FDA to retain Avastin's breast cancer approval by allowing an updated label as well as a risk evaluation and mitigation strategy and a medication guide. The company also reiterated its plan to undertake a confirmatory study of Avastin plus chemotherapy drug paclitaxel for HER2-negative metastatic breast cancer.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD